Schwangerschaft und Thrombophilie

Zusammenfassung

In der Schwangerschaft führen eine Reihe von erworbenen und angeborenen thrombophilen Faktoren zu einem komplikativen Schwangerschaftsausgang. Darüber hinaus ist erwiesen, daß thrombophile Faktoren ein zusätzliches Risiko darstellen, aufgrund dessen sich eine höhere Inzidenz von Präeklampsien, intrauterinem Fruchttod und wiederholtem Spontanabort ergeben kann.

Summary

In a number of adverse pregnancy outcome including preeclampsia, recurrent spontaneous abortion, restricted fetal growth and fetal death a role for thrombophilia (acquired and hereditable) has been postulated. Monitoring of acquired factors such as antiphospholipidantibodies and hereditable factors (factor V Leiden, prothrombin mutation) may help predict the occurrence of pregnancy complications.

Schlüsselwörter

Schwangerschaft - Thrombophilie - Thrombose - Präeklampsie - wiederholter Abort

Keywords

Pregnancy - thrombophilia - deep vein thrombosis - preeclampsia - recurrent abortion

• Literatur

• 1 Backos M, Chilcott I, Ray R, Regan L. Pregnancy complications in women with recurrent miscarriage and antiphospholipid-antibodie treated with aspirin and heparin. Hum Reprod 1997; 12: 61.
• 2 Bertina RM, Koeleman BCC, Koster T, Rosendaal FR, Dirven RJ, deRonde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 3 Bockarewa MI, Bremme K, Blombäck M. Arg 506-GLn mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-78.
• 4 Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997; 11: 72.
• 5 Brenner B, Lanier N, Tahler I. HELLP syndrome associated with factor V R 506 Q Mutation. Br J Haematol 1996; 92: 999.
• 6 Brenner B, Sarig G, Weiner Z, Youmis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphismus are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
• 7 Clark AL, Branch DW, Silver RM. et al. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999; 93: 437.
• 8 Conard J, Horellou MH, van Dreden P, Lecomte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S. Thromb Haemost 1990; 63: 319-20.
• 9 Conard J, Horellou MH, van Dreden P, Samama M. Pregnancy and congenital deficiency in antithrombin III or protein C. Thromb Haemost 1987; 58: 39.
• 10 Cook G, Walker D, Mc Call F. Familiar thrombophilia and activated protein C resistance – thrombotic risk in pregnancy ?. Br J Haematol 1994; 87: 873-5.
• 11 Cumming AM, Tait RC, Fildes S, Young A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725.
• 12 De Stefano V, Mastrangelo S, Paciaroni K, Ireland M, Lane DA, Scirpa P, Bizzi B, Leone G. Thrombotic risk during pregnancy and puerperium in women with APC resistence – effective subcutaneous heparin prophylaxis in a pregnant patients. Thromb Haemost 1995; 74: 793-4.
• 13 De Vries JIP, Dekker GA, Huijgens PC. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248.
• 14 Dekker GA, de Vries JP, Doelitsch PM, Huijens PC, von Blomberg B ME, van Geijn HP. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1996; 173: 1042.
• 15 DeSwiet M. Thromboembolic disease. In: James DK. et al. High risk pregnancy. Saunders WP; 1999
• 16 Dilley A, Hopper W, Janil ME, Austin H, Evatt R, Philipp CS. The role of four coagulation genes in thrombosis during pregnancy: Factor V Leiden, Prothrombin 20210, MTHFR, ACE. Thromb Haemost 1999; 82 (Suppl. 01) 227.
• 17 Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902.
• 18 Doggen CJM, Kunz G, Rosendaal FR. A mutation in the thrombomodulin-gen, 127 G to A loading for Ala25Thr and the risk myocardial infarction in men. Thromb Haemost 1998; 80: 743.
• 19 Eldor A, Kupferminc MJ, Steinmann N, Many A, Bar-Am A, Jaffa A, Fait G, Lesing JB. LMW Heparin during pregnancy for women with previous obstetric complications and thrombophilia. Thromb Haemost 1999; 82 (Suppl. I): 58.
• 20 Friederich PW, Samson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Büller HR, Girolami A, Prins MH. Frequency of pregnancy related thromboembolism in anticoagulant factor deficient women: Implications for prophylaxis. Ann Int Med 1996; 125: 955-60.
• 21 Gerhardt A, Zotz RB, Struwe S, Maruhn-Delowski B, Beckmann MW, Bender HG, Scharf RE. Predictors of thrombosis in pregnancy and puerperium. Thromb Haemost 1999; 82 (Suppl. I): 226.
• 22 Girling J, deSwiet M. Inherited thrombophilia and pregnancy. Current Opinion Obstet Gynecol 1998; 10: 135-44.
• 23 Grandone E, Margaglione M, Colaizzo D. Factor V Leiden, C >T MTHFR Polymorphismus and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052.
• 24 Grandone E, Margaglione M, Colaizzo D. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81: 349.
• 25 Greer IA. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynecology. Bailliers Clin Obstet Gynecol 1997; 11: 403-30.
• 26 Hallak M, Senderowicz J, Cassel A, Shapira Ch, Agkai E, Auslender R, Abramovici H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
• 27 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
• 28 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 13: 76-89.
• 29 Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Evenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use. Prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.
• 30 Katano K, Aoki K, Sasa H. β₂-glycoprotein1-dependent anticardiolipin-antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509.
• 31 Krauss Th, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelet syndrome. Obstet Gynecol 1998; 92: 457.
• 32 Kupferminc MJ, Eldor A, Steinman N. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9.
• 33 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss:Treatment with heparin and low-dose aspirin is superior to lowdose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584.
• 34 Landy HJ, Kessler C, Kelly WK, Weingold AB. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies. Am J Perinat 1992; 9: 146.
• 35 Laskin CA, Bombardier C, Hannah ME. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148.
• 36 Lima F, Khamashta MA, Buchanan NMM. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheum 1996; 14: 131.
• 37 Lindoff C, Ingemarson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol 1997; 176: 457.
• 38 Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439.
• 39 Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: Poller L, Ludlam CA. Blood coagulation. Churchill Livingstone; 1997
• 40 Lubbe WF, Liggins GC. Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 1985; 153: 322.
• 41 Lynch NA, Mariar R, Murphy J. Antiphospholipidantibodies in predicting advers pregnancy outcome. Ann Int Med 1994; 120: 470.
• 42 Macklon NS, Greer IA. Venous thrombembolic diseaese in obstetrics and gynaecology. The Scottish experience. Scot Med J 1996; 41: 83-6.
• 43 McColl ND, Ramsay J, Tait R, Walker JD, McCall F, Conkie JA, Carty MI, Greer IA. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.
• 44 Öhlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997; 78: 396.
• 45 Out HJ, Bruinse HW, Christiaens GCML. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26.
• 46 Pampus MG, Dekker GA, Wolf H. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146.
• 47 Pampus van MG, Koopman MMW, Wolf H. Lipoprotein (a) concentrations in women with a history of severe preeclampsia – a case control study. Thromb Haemost 1999; 82: 10.
• 48 Poort SR, Rosedaal FR, Reimtsa PH, Bertina RM. A common genetic variation in the 3’-´ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698.
• 49 Preston FE, Rosendaal FR, Walker ID, Berntorp E, van der Meer F, Conard J, Andres JCS, Lutetzky A, Arcieri P, Pabinger I, Legnani C, Scharrer I. Thromboprophylaxis in pregnancy reduces fetal loss in women with heretable thrombophilia: a prospective EPCOT study. Thromb Haemost 1999; 82 (Suppl I): 227.
• 50 Preston FE, Rosendaal FR, Walter ID. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913.
• 51 Rai R, Regan L, Hadley E, Dave M, Kohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Hematol 1996; 92: 489.
• 52 Rand JH, Wu XX, Guller S. Reduction of annexin V (placental anticoagulant protein I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol 1994; 171: 1566.
• 53 Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-19.
• 54 Sarig G, Hoffmann R, Youmis J, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with pregnancy loss associated with late pregnancy wastage. Thromb Haemost 1999; 82 (Suppl. I): 226.
• 55 Schneider DM, Heilmann L, von Tempelhoff GF, Kuse S, Knirsch K, Vogel W. Antiphospholipid antibodies and haematological defects in women with a history of preeclampsia/HELLP and outcome of IVIG treated pregnancies. Ann Haematol 1999; 78 (Suppl. I): 455.
• 56 Schneider DM, von Tempelhoff GF, Hoppenstaedt D, Fareed J, Heilmann L. Die erworbene Resistenz gegen aktiviertes Protein C in der Schwangerschaft. Z Geburtsh Neonatol 1998; 202: 107.
• 57 Triplett DA. Obstetrical complications associated with antiphospholipid antibodies. In: Coulam CB, Faulk WP, McIntyre JA. Immunological Obstetrics. Norton Medical Books; 1992
• 58 Valensise H, Vaquero E, de Carolis C. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diag 1995; 15: 509.
• 59 Vincente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM. Risk of thrombosis during pregnancy and postpartum in hereditary thrombophilia. Am J Haematol 1994; 46: 151-2.
• 60 Walker MC, Smith GM, Perkins SL. Changes in homocystein levels during normal pregnancy. Am J Obstet Gynecol 1999; 180: 660.
• 61 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555.